The Bayer satellite symposium was introduced by Prof Fred Saad, who gave an introduction into the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC). Results from the recent Phase III ALpharadin in SYMptomatic Prostate Cancer (ALSYMPCA) study were also presented. Profs Kramer, Tombal, and Gschwend then each presented case studies on patients they had treated with radium-223. Each speaker also provided their own personal view and recommendations for use of radium-223 based on their experience with these patients. Prof Gschwend concluded the symposium with important considerations for the urologist in using radium-223 in mCRPC.
Please view the full content in the pdf above.